Introduction: What is PTSD?
Post-Traumatic Stress Disorder (PTSD) is a mental health condition that can develop after an individual experiences or witnesses a life-threatening event. Unlike normal stress reactions, PTSD involves prolonged, severe symptoms that can interfere with daily life. Common symptoms include intrusive memories of the traumatic event, emotional numbness, avoidance of reminders of the trauma, and heightened reactions to stress (hyperarousal). While many individuals may experience short-term distress after trauma, PTSD can last for years, severely affecting the person’s mental health, relationships, and overall well-being.
Research suggests that approximately 6-9% of the general population will experience PTSD at some point, with the rates climbing to 25% in individuals exposed to extreme trauma, such as combat veterans, survivors of abuse, and healthcare workers during the COVID-19 pandemic. PTSD often doesn’t occur in isolation, with many individuals also suffering from anxiety, depression, chronic pain, substance use disorders, and cognitive issues. This comorbidity makes the treatment of PTSD especially complex.
The Role of Neuropeptide S in PTSD
Recent research has brought a promising focus on a brain chemical called Neuropeptide S (NPS), which could play a pivotal role in PTSD and its associated symptoms. NPS is a neuropeptide, a small protein that helps regulate several processes in the brain, such as arousal, anxiety, and fear responses. Its receptor, NPSR, is a G-protein-coupled receptor that, when activated by NPS, influences the brain’s stress-response systems.
According to a review of studies published between 2000 and 2024, the NPS-NPSR system is becoming a key area of interest for understanding how PTSD develops and how it can be treated. This system, which regulates various emotional and stress responses, has been linked to several psychiatric conditions, including PTSD.
Genetic Factors and PTSD Risk
A critical finding from this body of research is the connection between a genetic variation in the NPSR gene, specifically the rs324981 A/T polymorphism, and the risk of developing PTSD. Individuals who carry the T allele of this polymorphism have been found to be more vulnerable to PTSD after experiencing trauma, possibly due to increased NPSR activity. This discovery could eventually lead to genetic screening tools to identify individuals at higher risk for PTSD, paving the way for early intervention strategies.
NPS Effects on PTSD Symptoms
The studies reviewed show that NPS plays a crucial role in reducing anxiety, fear, and stress-related symptoms, which are hallmark features of PTSD. In animal models, administering NPS has been shown to alleviate PTSD-like behaviors, such as anxiety, freezing, and heightened responses to fear. For example, when NPS was injected into the brain regions associated with fear, like the amygdala, animals showed reduced fear responses and better stress recovery.
Additionally, NPS has been found to accelerate the extinction of fear memories, a critical process in treating PTSD. In the brain, fear memories can become ingrained, making it difficult for individuals to move past the traumatic experience. By enhancing the brain’s ability to “unlearn” these memories, NPS could play a vital role in helping PTSD patients recover.
Broad Applications of NPS
The implications of NPS extend beyond just PTSD. The neuropeptide has shown potential in treating several comorbid conditions associated with PTSD, such as chronic pain, substance use disorders, and even eating disorders. NPS appears to dampen pain perception and reduce drug cravings, suggesting it could be a versatile treatment for individuals struggling with multiple conditions at once.
In addiction models, NPS reduced alcohol and opioid consumption, highlighting its potential in treating substance use disorders. This multimodal effect—tackling both PTSD and related disorders—makes NPS an exciting therapeutic candidate.
Challenges and Future Directions
While the preclinical data on NPS is promising, there are still challenges in translating these findings into human treatments. One significant issue is that NPS is quickly degraded in the body and does not easily cross the blood-brain barrier, which limits its effectiveness as a therapeutic drug. However, researchers are exploring alternative delivery methods, such as nasal sprays, which could bypass the blood-brain barrier and deliver NPS directly to the brain.
Additionally, scientists are investigating new drug-like compounds that could mimic the effects of NPS, such as biased NPSR agonists, which selectively activate the receptor in ways that might be more beneficial for treating PTSD. These innovative approaches could ultimately lead to more effective treatments for PTSD and other neuropsychiatric conditions.
Conclusion: A New Path for PTSD Treatment
The NPS-NPSR system has emerged as a key player in regulating PTSD and its associated disorders. By influencing stress-related brain circuits, NPS holds the potential to alleviate core PTSD symptoms, including anxiety, fear, and hyperarousal. Moreover, its broad therapeutic effects on comorbid conditions like pain and substance use disorder make it a promising candidate for multimodal treatments.
As research progresses, the challenge remains to find safe, effective ways to deliver NPS to the brain. With continued exploration, NPS could offer new hope for those suffering from PTSD and related disorders, helping them lead healthier, more balanced lives.
Key Takeaways
-
PTSD is a serious mental health condition that often occurs alongside other disorders.
-
Neuropeptide S (NPS) and its receptor (NPSR) have been identified as key regulators of PTSD symptoms.
-
A genetic variation in NPSR increases the risk of developing PTSD after trauma.
-
NPS reduces anxiety, fear, and pain, showing promise in treating PTSD and its comorbidities.
-
Challenges in delivery methods and further research are necessary to develop effective NPS-based therapies.
By focusing on NPS and its receptor, researchers are opening up new avenues for treating PTSD and improving the lives of those affected by this debilitating disorder.
The translation of the preceding English text in Chinese:
引言：什么是PTSD？
创伤后应激障碍（PTSD）是一种心理健康疾病，通常在个体经历或目睹了危及生命的事件后发生。与正常的应激反应不同，PTSD包括长期、严重的症状，严重干扰日常生活。常见的症状包括创伤事件的侵入性记忆、情感麻木、回避创伤的提醒，以及对压力的过度反应（过度警觉）。虽然许多个体在创伤后可能会经历短期的困扰，但PTSD可能会持续多年，严重影响个体的心理健康、人际关系和整体福祉。
研究表明，大约6-9%的普通人群在某个时刻会经历PTSD，而在遭遇极端创伤的个体中，如战斗退伍军人、虐待幸存者和在COVID-19大流行期间的医护人员中，患病率可高达25%。PTSD通常并非单独发生，许多患者还会遭受焦虑、抑郁、慢性疼痛、物质使用障碍和认知问题。这种共病使得PTSD的治疗尤其复杂。
神经肽S在PTSD中的作用
最近的研究聚焦于一种被称为神经肽S（NPS）的脑部化学物质，这种物质可能在PTSD及其相关症状中发挥重要作用。NPS是一种神经肽，它是调节脑内多个过程的小蛋白质，例如唤醒、焦虑和恐惧反应。它的受体，NPSR，是一种G蛋白偶联受体，当NPS激活该受体时，能够影响大脑的应激反应系统。
根据2000年至2024年间发表的研究综述，NPS-NPSR系统正成为理解PTSD如何发展及其如何治疗的关键领域。这个系统调节着各种情绪和应激反应，已与包括PTSD在内的多种精神病症相关联。
遗传因素与PTSD风险
这一领域的一个重要发现是，NPSR基因中的一种遗传变异，特别是rs324981 A/T多态性，与PTSD的风险有关。携带这种变异T等位基因的个体在经历创伤后发现自己更容易患上PTSD，这可能是由于NPSR活性增加。这个发现最终可能会促使开发基因筛查工具，帮助识别高风险个体，为早期干预提供机会。
NPS对PTSD症状的影响
研究表明，NPS在减少焦虑、恐惧和应激相关症状方面发挥着至关重要的作用，而这些正是PTSD的标志性特征。在动物模型中，给动物注射NPS显示出缓解PTSD样行为的效果，如焦虑、僵直以及对恐惧的过度反应。例如，当NPS被注射到与恐惧相关的大脑区域，如杏仁核时，动物显示出减少的恐惧反应和更好的应激恢复。
此外，研究还发现，NPS加速了恐惧记忆的消退，这是治疗PTSD的关键过程。在大脑中，恐惧记忆可能会变得根深蒂固，导致个体难以从创伤经验中走出来。通过增强大脑“忘记”这些记忆的能力，NPS可能在帮助PTSD患者恢复方面发挥重要作用。
NPS的广泛应用
NPS的意义不仅限于PTSD。研究表明，这种神经肽在治疗与PTSD相关的共病症状方面也具有潜力，如慢性疼痛、物质使用障碍，甚至进食障碍。NPS似乎能够减轻疼痛感知并减少药物渴求，这表明它可能成为同时治疗多种疾病的有效治疗方法。
在成瘾模型中，NPS减少了酒精和阿片类药物的消费，凸显了它在治疗物质使用障碍中的潜力。这种多模式效应——同时处理PTSD和相关疾病——使NPS成为一个令人兴奋的治疗候选物。
挑战与未来方向
尽管NPS在前临床数据上表现出色，但将这些发现转化为人类治疗仍然面临挑战。一个重大问题是NPS在体内迅速降解，且难以跨越血脑屏障，这限制了其作为治疗药物的效果。然而，研究人员正在探索替代的给药方式，如鼻喷雾剂，这些方式可以绕过血脑屏障，将NPS直接输送到大脑。
此外，科学家们还在研究能够模仿NPS效应的新药物化合物，如偏向性NPSR激动剂，这些激动剂以有利于治疗PTSD的方式选择性激活受体。这些创新的方法最终可能会带来更有效的PTSD及其他神经精神疾病的治疗方案。
结论：PTSD治疗的新路径
NPS-NPSR系统已经成为调节PTSD及其相关疾病的关键因素。通过影响与应激相关的大脑回路，NPS有潜力缓解PTSD的核心症状，包括焦虑、恐惧和过度警觉。此外，它对共病症状如疼痛和物质使用障碍的广泛治疗效果，使其成为多模式治疗的有前景的候选物。
随着研究的进展，如何安全、有效地将NPS输送到大脑仍然是一个挑战。随着进一步的探索，NPS可能为那些受PTSD和相关疾病困扰的人们提供新的希望，帮助他们过上更加健康、平衡的生活。
关键要点
-
PTSD是一种严重的心理健康障碍，通常与其他疾病共同发生。
-
神经肽S（NPS）及其受体（NPSR）已被确认是PTSD症状的关键调节因素。
-
NPSR中的遗传变异增加了创伤后发展PTSD的风险。
-
NPS减少焦虑、恐惧和疼痛，在治疗PTSD及其共病症状方面表现出希望。
-
需要解决给药方法和进一步的研究，以开发有效的基于NPS的治疗方案。
通过专注于NPS及其受体，研究人员正在为治疗PTSD开辟新的途径，改善受此疾病困扰者的生活。
Reference:
Zhi-cheng Zhu, Xue-jing Han, Zhen He, Meng-yang Liu, Ning Wu, Xiang-min Tong, Fei Li
Neuropeptide S pathway in PTSD and neuropsychiatric disorders: A review.
Biomol Biomed [Internet]. 2025 Aug. 4 [cited 2025 Nov. 26];26(2):227–239.
Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/12861
Additional information:
We invite submissions for our upcoming thematic issues, including:
- Immune Prediction and Prognostic Biomarkers in Immuno-Oncology
- Artificial Intelligence and Machine Learning in disease diagnosis and treatment target identification
More news: Blog
Editor: Merima Hadžić
Leave a Reply